4 stock ideas I brought back from the JPMorgan Healthcare Conference and…
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from the Covid straitjacket that so many of these companies got caught up in. The pandemic obscured so much of the growth as Abbott Labs , for example, poured money into BinaxNOW tests, and Regeneron developed a rapid response drug. Pfizer went after vaccines and rapid responses, and the drug stores shifted resources to Covid immunity shots. Now, with Covid behind them, we are seeing the true earnings power of so many terrific companies. For our newest Bullpen additions , we…